Welcome to our book review site go-pdf.online!

You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.

Sign up

Targeting the Microenvironment Niche in Hematologic Malignancies
  • Language: en
  • Pages: 193
Multiple Myeloma
  • Language: en
  • Pages: 216

Multiple Myeloma

  • Type: Book
  • -
  • Published: 2018
  • -
  • Publisher: Unknown

None

Targeting the Microenvironment Niche in Solid Tumors
  • Language: en
  • Pages: 155

Targeting the Microenvironment Niche in Solid Tumors

None

Management of Bone Disease and Kidney Failure in Multiple Myeloma
  • Language: en
  • Pages: 213

Management of Bone Disease and Kidney Failure in Multiple Myeloma

This pocket guide provides a concise yet comprehensive overview of the two most prominent clinical features of multiple myeloma (MM), bone disease and renal failure. The first half of the text reviews critical aspects of bone disease in MM, including pathophysiology, the use of imaging modalities and drugs in treatment, and the role of orthopedic surgery. The latter half of the book reviews major components of kidney disease in MM, from pathophysiology to treatment. Written by experts in the field, Management of Bone Disease and Kidney Failure in Multiple Myeloma: A Pocket Guide is a valuable resource for clinicians and practitioners who manage patients afflicted with multiple myeloma.

Bispecific Antibodies for T-Cell Based Immunotherapy
  • Language: en
  • Pages: 97

Bispecific Antibodies for T-Cell Based Immunotherapy

CK is affiliated with the Roche Innovation Center Zurich, holds stocks and has patents with Hoffmann-La Roche company. NKC reports receiving commercial research grants from Y-mabs Therapeutics and Abpro-Labs Inc.; holding ownership interest/equity/options in Y-Mabs Therapeutics Inc., and in Abpro-Labs, and owning stock options in Eureka Therapeutics. NKC is the inventor of pending and issued patents filed by MSK, including hu3F8 and 8H9 licensed to Ymabs Therapeutics, beta-glucan to Biotec Pharmacon, and HER2 bispecific antibody to Abpro-labs. NKC is an advisory board member for Abpro-Labs and Eureka Therapeutics

Novel Diagnostic Tools and Biomarkers in Hematologic Malignancies
  • Language: en
  • Pages: 218
AACR 2018 Proceedings: Abstracts 1-3027
  • Language: en

AACR 2018 Proceedings: Abstracts 1-3027

None

Testis cancer: genes, environment, hormones
  • Language: en
  • Pages: 88

Testis cancer: genes, environment, hormones

Testicular cancer (TC) is the most common cancer in males aged 20-40 years, with a worldwide incidence of 7.5 per 100,000, but the rates vary considerably between countries and ethnic groups and there is evidence also for an increasing incidence in last decades. About 95% of all TCs are represented by testicular germ cell tumors (TGCTs), which include seminoma and non-seminoma histological types. It is generally assumed that the development of TGCT is under endocrine control. In particular, unbalanced androgen/estrogen levels and/or activity are believed to represent the key events for TGCT development and progression. Furthermore, recent evidence has suggested genetic association of TGCT wi...

Personalverzeichnis
  • Language: de
  • Pages: 606

Personalverzeichnis

  • Type: Book
  • -
  • Published: 2004
  • -
  • Publisher: Unknown

None